context stringlengths 21 33.9k | category stringclasses 2
values | entity stringlengths 1 12 | entity_type stringclasses 5
values | query stringlengths 97 3.31k | answer stringlengths 12 169 |
|---|---|---|---|---|---|
The weighted-average fair value of the options granted under all equity incentive plans during the years ended December 31, 2024 and 2023 was $ 1.49 and $ 1.96 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions: | text | 1.96 | perShareItemType | text: <entity> 1.96 </entity> <entity type> perShareItemType </entity type> <context> The weighted-average fair value of the options granted under all equity incentive plans during the years ended December 31, 2024 and 2023 was $ 1.49 and $ 1.96 per share, respectively, applying the Black-Scholes-Merton option pricing ... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
As of December 31, 2024, the Company had $ 351.8 million of U.S. Federal and state net operating losses, $ 10.9 million of research and development tax credits and $ 44.1 million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2025, the re... | text | 351.8 | monetaryItemType | text: <entity> 351.8 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had $ 351.8 million of U.S. Federal and state net operating losses, $ 10.9 million of research and development tax credits and $ 44.1 million of orphan drug tax credits available to carry forward.... | us-gaap:OperatingLossCarryforwards |
As of December 31, 2024, the Company had $ 351.8 million of U.S. Federal and state net operating losses, $ 10.9 million of research and development tax credits and $ 44.1 million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2025, the re... | text | 10.9 | monetaryItemType | text: <entity> 10.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had $ 351.8 million of U.S. Federal and state net operating losses, $ 10.9 million of research and development tax credits and $ 44.1 million of orphan drug tax credits available to carry forward. ... | us-gaap:TaxCreditCarryforwardAmount |
As of December 31, 2024, the Company had $ 351.8 million of U.S. Federal and state net operating losses, $ 10.9 million of research and development tax credits and $ 44.1 million of orphan drug tax credits available to carry forward. A portion of the net operating loss carryforwards will begin to expire in 2025, the re... | text | 44.1 | monetaryItemType | text: <entity> 44.1 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2024, the Company had $ 351.8 million of U.S. Federal and state net operating losses, $ 10.9 million of research and development tax credits and $ 44.1 million of orphan drug tax credits available to carry forward. ... | us-gaap:TaxCreditCarryforwardAmount |
The Company has a defined contribution plan under the Internal Revenue Code Section 401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. For the years ended December 31, 2024, 2023 a... | text | 211000 | monetaryItemType | text: <entity> 211000 </entity> <entity type> monetaryItemType </entity type> <context> The Company has a defined contribution plan under the Internal Revenue Code Section 401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of the... | us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount |
The Company has a defined contribution plan under the Internal Revenue Code Section 401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. For the years ended December 31, 2024, 2023 a... | text | 248000 | monetaryItemType | text: <entity> 248000 </entity> <entity type> monetaryItemType </entity type> <context> The Company has a defined contribution plan under the Internal Revenue Code Section 401(k). This plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer a portion of the... | us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount |
In July 2024, the Company’s Board of Directors approved a streamlined operating plan that included a reduction in the Company’s workforce by 26 employees, or approximately 80 % of its headcount. | text | 26 | integerItemType | text: <entity> 26 </entity> <entity type> integerItemType </entity type> <context> In July 2024, the Company’s Board of Directors approved a streamlined operating plan that included a reduction in the Company’s workforce by 26 employees, or approximately 80 % of its headcount. </context> | us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated |
In July 2024, the Company’s Board of Directors approved a streamlined operating plan that included a reduction in the Company’s workforce by 26 employees, or approximately 80 % of its headcount. | text | 80 | percentItemType | text: <entity> 80 </entity> <entity type> percentItemType </entity type> <context> In July 2024, the Company’s Board of Directors approved a streamlined operating plan that included a reduction in the Company’s workforce by 26 employees, or approximately 80 % of its headcount. </context> | us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent |
Employees affected by the reduction in force are entitled to receive severance payments and Company-funded medical insurance for a specific time. During the year ended December 31, 2024, the Company recognized $ 7.0 million of charges for severance and related benefits. | text | 7.0 | monetaryItemType | text: <entity> 7.0 </entity> <entity type> monetaryItemType </entity type> <context> Employees affected by the reduction in force are entitled to receive severance payments and Company-funded medical insurance for a specific time. During the year ended December 31, 2024, the Company recognized $ 7.0 million of charges... | us-gaap:RestructuringCharges |
The accrued severance liability of $ 3.5 million is payable within the next twelve months and has been included in accrued expenses on the balance sheet as of December 31, 2024. | text | 3.5 | monetaryItemType | text: <entity> 3.5 </entity> <entity type> monetaryItemType </entity type> <context> The accrued severance liability of $ 3.5 million is payable within the next twelve months and has been included in accrued expenses on the balance sheet as of December 31, 2024. </context> | us-gaap:PaymentsForRestructuring |
The Company recorded $ 0.4 million of impairment charges related to its facility operating lease and accelerated depreciation on property and equipment during the year ended December 31, 2024. | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> The Company recorded $ 0.4 million of impairment charges related to its facility operating lease and accelerated depreciation on property and equipment during the year ended December 31, 2024. </context> | us-gaap:RestructuringReserveAcceleratedDepreciation |
Accrued interest receivables on debt securities available-for-sale were $ 11.2 million and $ 4.7 million, respectively, as of December 31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is ex... | text | 11.2 | monetaryItemType | text: <entity> 11.2 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivables on debt securities available-for-sale were $ 11.2 million and $ 4.7 million, respectively, as of December 31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivable... | us-gaap:InterestReceivableCurrent |
Accrued interest receivables on debt securities available-for-sale were $ 11.2 million and $ 4.7 million, respectively, as of December 31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivables. For the purposes of identifying and measuring an impairment, accrued interest is ex... | text | 4.7 | monetaryItemType | text: <entity> 4.7 </entity> <entity type> monetaryItemType </entity type> <context> Accrued interest receivables on debt securities available-for-sale were $ 11.2 million and $ 4.7 million, respectively, as of December 31, 2023 and 2022. We do not measure an allowance for credit losses for accrued interest receivables... | us-gaap:InterestReceivableCurrent |
Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining... | text | 17.8 | monetaryItemType | text: <entity> 17.8 </entity> <entity type> monetaryItemType </entity type> <context> Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvem... | us-gaap:Depreciation |
Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining... | text | 15.1 | monetaryItemType | text: <entity> 15.1 </entity> <entity type> monetaryItemType </entity type> <context> Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvem... | us-gaap:Depreciation |
Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvements are depreciated over the shorter of their estimated useful lives or the remaining... | text | 10.9 | monetaryItemType | text: <entity> 10.9 </entity> <entity type> monetaryItemType </entity type> <context> Property and equipment are stated at cost and depreciated over the estimated useful lives of the assets using the straight-line method. Equipment is depreciated over an average estimated useful life of 3 to 7 years. Leasehold improvem... | us-gaap:Depreciation |
We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 91 % of our total product sales for 2023 and approximately 98 % of ou... | text | 91 | percentItemType | text: <entity> 91 </entity> <entity type> percentItemType </entity type> <context> We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented ... | us-gaap:ConcentrationRiskPercentage1 |
We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented approximately 91 % of our total product sales for 2023 and approximately 98 % of ou... | text | 98 | percentItemType | text: <entity> 98 </entity> <entity type> percentItemType </entity type> <context> We have entered into agreements for the distribution of INGREZZA with a limited number of specialty pharmacy providers and distributors and all of our product sales of INGREZZA are to these customers. Four of these customers represented ... | us-gaap:ConcentrationRiskPercentage1 |
Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $ 159.9 million for 2023, $ 149.7 million for 2022 and $ 139.8 million for 2021. | text | 159.9 | monetaryItemType | text: <entity> 159.9 </entity> <entity type> monetaryItemType </entity type> <context> Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $ 159.9 million for 2023, $ 149.7 million for 2022 and $ 139.8 million for 2021. </context> | us-gaap:AdvertisingExpense |
Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $ 159.9 million for 2023, $ 149.7 million for 2022 and $ 139.8 million for 2021. | text | 149.7 | monetaryItemType | text: <entity> 149.7 </entity> <entity type> monetaryItemType </entity type> <context> Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $ 159.9 million for 2023, $ 149.7 million for 2022 and $ 139.8 million for 2021. </context> | us-gaap:AdvertisingExpense |
Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $ 159.9 million for 2023, $ 149.7 million for 2022 and $ 139.8 million for 2021. | text | 139.8 | monetaryItemType | text: <entity> 139.8 </entity> <entity type> monetaryItemType </entity type> <context> Advertising costs are expensed as selling, general and administrative when incurred. Advertising expense was $ 159.9 million for 2023, $ 149.7 million for 2022 and $ 139.8 million for 2021. </context> | us-gaap:AdvertisingExpense |
In 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25 % fixed-rate convertible senior notes due May 15, 2024 in cash upon conversion and to settle any conversion premium in either cash or shares of our common ... | text | 2.25 | percentItemType | text: <entity> 2.25 </entity> <entity type> percentItemType </entity type> <context> In 2021, we entered into the First Supplemental Indenture to the 2017 Indenture, pursuant to which we irrevocably elected to settle the principal amount of the 2.25 % fixed-rate convertible senior notes due May 15, 2024 in cash upon co... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
In connection with the agreement, we paid Heptares $ 100.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&D in 2021 as the license had no foreseeable alternative future use. We accounted for the transaction as an asset acquisition as the set of acquired assets did not constitut... | text | 100.0 | monetaryItemType | text: <entity> 100.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the agreement, we paid Heptares $ 100.0 million upfront, which, including certain transaction-related costs, was expensed as IPR&D in 2021 as the license had no foreseeable alternative future use. We accounted for ... | us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff |
In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $ 30.0 million, which was expensed as R&D in 2022. | text | 30.0 | monetaryItemType | text: <entity> 30.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the FDA's acceptance of our investigational new drug application for NBI-1117568 for the treatment of schizophrenia in June 2022, we paid Heptares a milestone of $ 30.0 million, which was expensed as R&D in 2022. </... | us-gaap:ResearchAndDevelopmentExpense |
In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in 2022, we paid Takeda a milestone of $ 5.0 million, which was expensed as R&D in 2022. | text | 5.0 | monetaryItemType | text: <entity> 5.0 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the approval of our clinical trial application for NBI-1070770 for the treatment of major depressive disorder in 2022, we paid Takeda a milestone of $ 5.0 million, which was expensed as R&D in 2022. </context> | us-gaap:ResearchAndDevelopmentExpense |
In connection with the agreement, we purchased approximately 1.4 million shares (at $ 14.196 per share) of Xenon common stock in 2019. The purchased shares were recorded at a fair value of $ 14.1 million after considering Xenon’s stock price and certain transfer restrictions that were applicable to the shares on the me... | text | 14.196 | perShareItemType | text: <entity> 14.196 </entity> <entity type> perShareItemType </entity type> <context> In connection with the agreement, we purchased approximately 1.4 million shares (at $ 14.196 per share) of Xenon common stock in 2019. The purchased shares were recorded at a fair value of $ 14.1 million after considering Xenon’s st... | us-gaap:SharePrice |
In connection with the agreement, we purchased approximately 1.4 million shares (at $ 14.196 per share) of Xenon common stock in 2019. The purchased shares were recorded at a fair value of $ 14.1 million after considering Xenon’s stock price and certain transfer restrictions that were applicable to the shares on the me... | text | 14.1 | monetaryItemType | text: <entity> 14.1 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the agreement, we purchased approximately 1.4 million shares (at $ 14.196 per share) of Xenon common stock in 2019. The purchased shares were recorded at a fair value of $ 14.1 million after considering Xenon’s stoc... | us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue |
In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $ 10.0 million, including a purchase of approximately 0.3 million shares (at $ 19.9755 per share) of Xenon common sto... | text | 19.9755 | perShareItemType | text: <entity> 19.9755 </entity> <entity type> perShareItemType </entity type> <context> In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $ 10.0 million, including a ... | us-gaap:SharePrice |
In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $ 10.0 million, including a purchase of approximately 0.3 million shares (at $ 19.9755 per share) of Xenon common sto... | text | 4.6 | monetaryItemType | text: <entity> 4.6 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $ 10.0 million, including a purc... | us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue |
In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $ 10.0 million, including a purchase of approximately 0.3 million shares (at $ 19.9755 per share) of Xenon common sto... | text | 5.4 | monetaryItemType | text: <entity> 5.4 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the regulatory approval of our clinical trial application in Europe for NBI-921352 for the treatment of focal onset seizures in adults in 2021, we paid Xenon a regulatory milestone of $ 10.0 million, including a purc... | us-gaap:ResearchAndDevelopmentExpense |
study protocol in 2022, we paid Xenon a regulatory milestone of $ 15.0 million, including a purchase of approximately 0.3 million shares (at $ 31.855 per share) of Xenon common stock. The purchased shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The r... | text | 31.855 | perShareItemType | text: <entity> 31.855 </entity> <entity type> perShareItemType </entity type> <context> study protocol in 2022, we paid Xenon a regulatory milestone of $ 15.0 million, including a purchase of approximately 0.3 million shares (at $ 31.855 per share) of Xenon common stock. The purchased shares were recorded at a fair val... | us-gaap:SharePrice |
study protocol in 2022, we paid Xenon a regulatory milestone of $ 15.0 million, including a purchase of approximately 0.3 million shares (at $ 31.855 per share) of Xenon common stock. The purchased shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The r... | text | 7.7 | monetaryItemType | text: <entity> 7.7 </entity> <entity type> monetaryItemType </entity type> <context> study protocol in 2022, we paid Xenon a regulatory milestone of $ 15.0 million, including a purchase of approximately 0.3 million shares (at $ 31.855 per share) of Xenon common stock. The purchased shares were recorded at a fair value ... | us-gaap:EquitySecuritiesFvNiCost |
study protocol in 2022, we paid Xenon a regulatory milestone of $ 15.0 million, including a purchase of approximately 0.3 million shares (at $ 31.855 per share) of Xenon common stock. The purchased shares were recorded at a fair value of $ 7.7 million after considering Xenon’s stock price on the measurement date. The r... | text | 7.3 | monetaryItemType | text: <entity> 7.3 </entity> <entity type> monetaryItemType </entity type> <context> study protocol in 2022, we paid Xenon a regulatory milestone of $ 15.0 million, including a purchase of approximately 0.3 million shares (at $ 31.855 per share) of Xenon common stock. The purchased shares were recorded at a fair value ... | us-gaap:ResearchAndDevelopmentExpense |
In connection with the 2019 Voyager Agreement, we purchased approximately 4.2 million shares (at $ 11.9625 per share) of Voyager common stock (the 2019 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the... | text | 11.9625 | perShareItemType | text: <entity> 11.9625 </entity> <entity type> perShareItemType </entity type> <context> In connection with the 2019 Voyager Agreement, we purchased approximately 4.2 million shares (at $ 11.9625 per share) of Voyager common stock (the 2019 Purchased Shares), which are subject to certain transfer, beneficial ownership,... | us-gaap:SharePrice |
In connection with the 2019 Voyager Agreement, we purchased approximately 4.2 million shares (at $ 11.9625 per share) of Voyager common stock (the 2019 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of up to three years from the effective date of the... | text | 54.7 | monetaryItemType | text: <entity> 54.7 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2019 Voyager Agreement, we purchased approximately 4.2 million shares (at $ 11.9625 per share) of Voyager common stock (the 2019 Purchased Shares), which are subject to certain transfer, beneficial ownership, an... | us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of... | text | 8.88 | perShareItemType | text: <entity> 8.88 </entity> <entity type> perShareItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subj... | us-gaap:SharePrice |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of... | text | 19.9 | percentItemType | text: <entity> 19.9 </entity> <entity type> percentItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subje... | us-gaap:EquityMethodInvestmentOwnershipPercentage |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of... | text | 31.3 | monetaryItemType | text: <entity> 31.3 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subj... | us-gaap:EquitySecuritiesFvNiCost |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of... | text | 143.9 | monetaryItemType | text: <entity> 143.9 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are sub... | us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of... | text | 15.5 | monetaryItemType | text: <entity> 15.5 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subj... | us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of... | text | 14.5 | monetaryItemType | text: <entity> 14.5 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subj... | us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of... | text | 8.7 | monetaryItemType | text: <entity> 8.7 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subje... | us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss |
In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subject to certain transfer, beneficial ownership, and voting restrictions for a period of... | text | 72.4 | monetaryItemType | text: <entity> 72.4 </entity> <entity type> monetaryItemType </entity type> <context> In connection with the 2023 Voyager Agreement, we paid Voyager $ 175.0 million upfront, including a purchase of approximately 4.4 million shares (at $ 8.88 per share) of Voyager common stock (the 2023 Purchased Shares), which are subj... | us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent |
(opicapone) in the U.S. and Canada. We launched ONGENTYS in the U.S. as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations in 2020. In 2023, we provided BIAL with written notice of termination of the license agreement to commercialize and market O... | text | 5.2 | monetaryItemType | text: <entity> 5.2 </entity> <entity type> monetaryItemType </entity type> <context> (opicapone) in the U.S. and Canada. We launched ONGENTYS in the U.S. as an FDA-approved add-on treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing motor fluctuations in 2020. In 2023, we provided BIAL with... | us-gaap:InventoryValuationReserves |
(valbenazine). We receive royalties at tiered percentage rates on MTPC net sales of valbenazine. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $ 20.0 million in 2022. ASC 606 provides a royalty exception for a sales-based or usage-based royalty promised in exchan... | text | 20.0 | monetaryItemType | text: <entity> 20.0 </entity> <entity type> monetaryItemType </entity type> <context> (valbenazine). We receive royalties at tiered percentage rates on MTPC net sales of valbenazine. In connection with MTPC's first commercial sale of DYSVAL in Japan, we received a milestone payment of $ 20.0 million in 2022. ASC 606 pr... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 16.7 million for 202... | text | 16.7 | monetaryItemType | text: <entity> 16.7 </entity> <entity type> monetaryItemType </entity type> <context> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie n... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 16.7 million for 202... | text | 21.2 | monetaryItemType | text: <entity> 21.2 </entity> <entity type> monetaryItemType </entity type> <context> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie n... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
(elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie net sales of elagolix and recognized elagolix royalty revenue of $ 16.7 million for 202... | text | 22.3 | monetaryItemType | text: <entity> 22.3 </entity> <entity type> monetaryItemType </entity type> <context> (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the U.S. for the treatment of heavy menstrual bleeding due to uterine fibroids in June 2020. We receive royalties at tiered percentage rates on AbbVie n... | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
On May 2, 2017, we completed a private placement of $ 517.5 million in aggregate principal amount of 2.25 % fixed-rate convertible senior notes due May 15, 2024 (the 2024 Notes) and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 ... | text | 517.5 | monetaryItemType | text: <entity> 517.5 </entity> <entity type> monetaryItemType </entity type> <context> On May 2, 2017, we completed a private placement of $ 517.5 million in aggregate principal amount of 2.25 % fixed-rate convertible senior notes due May 15, 2024 (the 2024 Notes) and entered into the 2017 Indenture with respect to the... | us-gaap:DebtInstrumentFaceAmount |
On May 2, 2017, we completed a private placement of $ 517.5 million in aggregate principal amount of 2.25 % fixed-rate convertible senior notes due May 15, 2024 (the 2024 Notes) and entered into the 2017 Indenture with respect to the 2024 Notes. Interest on the 2024 Notes is due semi-annually on May 15 and November 15 ... | text | 2.25 | percentItemType | text: <entity> 2.25 </entity> <entity type> percentItemType </entity type> <context> On May 2, 2017, we completed a private placement of $ 517.5 million in aggregate principal amount of 2.25 % fixed-rate convertible senior notes due May 15, 2024 (the 2024 Notes) and entered into the 2017 Indenture with respect to the 2... | us-gaap:DebtInstrumentInterestRateStatedPercentage |
In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 279.0 million in cash, which resulted in the reco... | text | 136.2 | monetaryItemType | text: <entity> 136.2 </entity> <entity type> monetaryItemType </entity type> <context> In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes f... | us-gaap:DebtInstrumentRepurchasedFaceAmount |
In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 279.0 million in cash, which resulted in the reco... | text | 186.9 | monetaryItemType | text: <entity> 186.9 </entity> <entity type> monetaryItemType </entity type> <context> In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes f... | us-gaap:RepaymentsOfDebt |
In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 279.0 million in cash, which resulted in the reco... | text | 210.8 | monetaryItemType | text: <entity> 210.8 </entity> <entity type> monetaryItemType </entity type> <context> In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes f... | us-gaap:DebtInstrumentRepurchasedFaceAmount |
In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 279.0 million in cash, which resulted in the reco... | text | 279.0 | monetaryItemType | text: <entity> 279.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes f... | us-gaap:RepaymentsOfDebt |
In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 279.0 million in cash, which resulted in the reco... | text | 70.0 | monetaryItemType | text: <entity> 70.0 </entity> <entity type> monetaryItemType </entity type> <context> In 2020, we repurchased $ 136.2 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of $ 186.9 million in cash. In 2022, we repurchased $ 210.8 million aggregate principal amount of the 2024 Notes fo... | us-gaap:GainsLossesOnExtinguishmentOfDebt |
The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $ 1,000 principal amount and equivalent to an initial conversion price of approximately $ 75.92 per share, reflecting a conversion premium of appro... | text | 75.92 | perShareItemType | text: <entity> 75.92 </entity> <entity type> perShareItemType </entity type> <context> The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $ 1,000 principal amount and equivalent to an initial conver... | us-gaap:DebtInstrumentConvertibleConversionPrice1 |
The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $ 1,000 principal amount and equivalent to an initial conversion price of approximately $ 75.92 per share, reflecting a conversion premium of appro... | text | 53.28 | perShareItemType | text: <entity> 53.28 </entity> <entity type> perShareItemType </entity type> <context> The initial conversion rate for the 2024 Notes, which is subject to adjustment in some events (as provided for in the 2017 Indenture), is 13.1711 shares of common stock per $ 1,000 principal amount and equivalent to an initial conver... | us-gaap:SharePrice |
We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130 % of the conversion price then in effect (equal to $ 98.70 as of December 31, 2023) for at least 20 trading days (whether or not consecutive) during any 30 co... | text | 130 | percentItemType | text: <entity> 130 </entity> <entity type> percentItemType </entity type> <context> We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130 % of the conversion price then in effect (equal to $ 98.70 as of December ... | us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger |
We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130 % of the conversion price then in effect (equal to $ 98.70 as of December 31, 2023) for at least 20 trading days (whether or not consecutive) during any 30 co... | text | 98.70 | perShareItemType | text: <entity> 98.70 </entity> <entity type> perShareItemType </entity type> <context> We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130 % of the conversion price then in effect (equal to $ 98.70 as of Decemb... | us-gaap:DebtInstrumentConvertibleStockPriceTrigger |
We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130 % of the conversion price then in effect (equal to $ 98.70 as of December 31, 2023) for at least 20 trading days (whether or not consecutive) during any 30 co... | text | 20 | integerItemType | text: <entity> 20 </entity> <entity type> integerItemType </entity type> <context> We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130 % of the conversion price then in effect (equal to $ 98.70 as of December 3... | us-gaap:DebtInstrumentConvertibleThresholdTradingDays |
We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130 % of the conversion price then in effect (equal to $ 98.70 as of December 31, 2023) for at least 20 trading days (whether or not consecutive) during any 30 co... | text | 30 | integerItemType | text: <entity> 30 </entity> <entity type> integerItemType </entity type> <context> We may redeem for cash all or part of the 2024 Notes if the last reported sale price (as defined in the 2017 Indenture) of our common stock has been at least 130 % of the conversion price then in effect (equal to $ 98.70 as of December 3... | us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 |
during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 1... | text | 20 | integerItemType | text: <entity> 20 </entity> <entity type> integerItemType </entity type> <context> during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on t... | us-gaap:DebtInstrumentConvertibleThresholdTradingDays |
during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 1... | text | 30 | integerItemType | text: <entity> 30 </entity> <entity type> integerItemType </entity type> <context> during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on t... | us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 |
during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 1... | text | 130 | percentItemType | text: <entity> 130 </entity> <entity type> percentItemType </entity type> <context> during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on ... | us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger |
during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than 1... | text | 98.70 | perShareItemType | text: <entity> 98.70 </entity> <entity type> perShareItemType </entity type> <context> during any calendar quarter (and only during such calendar quarter), if the last reported sale price of our common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending ... | us-gaap:DebtInstrumentConvertibleStockPriceTrigger |
Until the close of business on the scheduled trading day immediately preceding May 15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time. On January 4, 2024, we provided notice to the holders of the 2024 Notes electing to settle all conversions of the 2024 Notes in cash. As such, upon conversion, h... | text | 30 | integerItemType | text: <entity> 30 </entity> <entity type> integerItemType </entity type> <context> Until the close of business on the scheduled trading day immediately preceding May 15, 2024, holders of the 2024 Notes may convert the 2024 Notes at any time. On January 4, 2024, we provided notice to the holders of the 2024 Notes electi... | us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 |
If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100 % of the principal amount of the 2024 Notes to be repurchased, plus accrued and unpaid ... | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> If we undergo a fundamental change (as defined in the 2017 Indenture), subject to certain conditions, holders of the 2024 Notes may require us to repurchase for cash all or part of their 2024 Notes at a repurchase price equal to 100 % o... | us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed |
The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured indebtedness. The 2024 Notes do not contain any financial or operating covenants or an... | text | 100 | percentItemType | text: <entity> 100 </entity> <entity type> percentItemType </entity type> <context> The 2024 Notes are our general unsecured obligations that rank senior in right of payment to all of our indebtedness that is expressly subordinated in right of payment to the 2024 Notes, and equal in right of payment to our unsecured in... | us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed |
Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.7 million for 2023, 4.6 million for 2022 and 4.1 million for 2021. | text | 4.7 | sharesItemType | text: <entity> 4.7 </entity> <entity type> sharesItemType </entity type> <context> Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.7 million for 2023, 4.6 million for 2022 and 4.1 million for 2021. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.7 million for 2023, 4.6 million for 2022 and 4.1 million for 2021. | text | 4.6 | sharesItemType | text: <entity> 4.6 </entity> <entity type> sharesItemType </entity type> <context> Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.7 million for 2023, 4.6 million for 2022 and 4.1 million for 2021. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.7 million for 2023, 4.6 million for 2022 and 4.1 million for 2021. | text | 4.1 | sharesItemType | text: <entity> 4.1 </entity> <entity type> sharesItemType </entity type> <context> Shares which have been excluded from diluted per share amounts because their effect would have been anti-dilutive were 4.7 million for 2023, 4.6 million for 2022 and 4.1 million for 2021. </context> | us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
In May 2022, our stockholders approved an amendment of the 2020 Equity Incentive Plan (as so amended, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards, and other awards. As of Decem... | text | 10.5 | sharesItemType | text: <entity> 10.5 </entity> <entity type> sharesItemType </entity type> <context> In May 2022, our stockholders approved an amendment of the 2020 Equity Incentive Plan (as so amended, the Amended 2020 Plan). The Amended 2020 Plan provides for the grant of stock options, stock appreciation rights, restricted stock awa... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
In May 2011, we adopted the 2011 Equity Incentive Plan (the 2011 Plan). The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which no further awards can or will be made. | text | no | sharesItemType | text: <entity> no </entity> <entity type> sharesItemType </entity type> <context> In May 2011, we adopted the 2011 Equity Incentive Plan (the 2011 Plan). The 2011 Plan was a stockholder-approved plan pursuant to which outstanding awards have been made, but from which no further awards can or will be made. </context> | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized |
In May 2021, our stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan (as so amended and restated, the Amended 2018 ESPP). As of December 31, 2023, 0.5 million shares of common stock remain available for future issuance under the Amended 2018 ESPP. | text | 0.5 | sharesItemType | text: <entity> 0.5 </entity> <entity type> sharesItemType </entity type> <context> In May 2021, our stockholders approved an amendment and restatement of the 2018 Employee Stock Purchase Plan (as so amended and restated, the Amended 2018 ESPP). As of December 31, 2023, 0.5 million shares of common stock remain availabl... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant |
Typically, stock options have a 10-year term and vest over a three to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The B... | text | 45.19 | perShareItemType | text: <entity> 45.19 </entity> <entity type> perShareItemType </entity type> <context> Typically, stock options have a 10-year term and vest over a three to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
Typically, stock options have a 10-year term and vest over a three to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The B... | text | 32.05 | perShareItemType | text: <entity> 32.05 </entity> <entity type> perShareItemType </entity type> <context> Typically, stock options have a 10-year term and vest over a three to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
Typically, stock options have a 10-year term and vest over a three to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of stock options using the Black-Scholes option-pricing model on the date of grant. The B... | text | 45.02 | perShareItemType | text: <entity> 45.02 </entity> <entity type> perShareItemType </entity type> <context> Typically, stock options have a 10-year term and vest over a three to four-year period. The exercise price of stock options granted is equal to the closing price of our common stock on the date of grant. We estimate the fair value of... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue |
The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and $ 20.7 million for 2021. | text | 39.9 | monetaryItemType | text: <entity> 39.9 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and ... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and $ 20.7 million for 2021. | text | 39.7 | monetaryItemType | text: <entity> 39.7 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and ... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and $ 20.7 million for 2021. | text | 58.0 | monetaryItemType | text: <entity> 58.0 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and ... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue |
The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and $ 20.7 million for 2021. | text | 55.5 | monetaryItemType | text: <entity> 55.5 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and ... | us-gaap:ProceedsFromStockOptionsExercised |
The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and $ 20.7 million for 2021. | text | 37.0 | monetaryItemType | text: <entity> 37.0 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and ... | us-gaap:ProceedsFromStockOptionsExercised |
The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and $ 20.7 million for 2021. | text | 20.7 | monetaryItemType | text: <entity> 20.7 </entity> <entity type> monetaryItemType </entity type> <context> The total intrinsic value of stock options exercised was $ 39.9 million for 2023, $ 39.7 million for 2022 and $ 58.0 million for 2021. Cash received from stock option exercises was $ 55.5 million for 2023, $ 37.0 million for 2022 and ... | us-gaap:ProceedsFromStockOptionsExercised |
RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $ 101.0 million for 2023, $ 72.4 mi... | text | 101.0 | monetaryItemType | text: <entity> 101.0 </entity> <entity type> monetaryItemType </entity type> <context> RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of iss... | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested |
RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $ 101.0 million for 2023, $ 72.4 mi... | text | 72.4 | monetaryItemType | text: <entity> 72.4 </entity> <entity type> monetaryItemType </entity type> <context> RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issu... | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested |
RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issuance. The total fair value of RSUs that vested was $ 101.0 million for 2023, $ 72.4 mi... | text | 64.3 | monetaryItemType | text: <entity> 64.3 </entity> <entity type> monetaryItemType </entity type> <context> RSUs typically vest over a four-year period and may be subject to a deferred delivery arrangement at the election of eligible employees. The fair value of RSUs is based on the closing sale price of our common stock on the date of issu... | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested |
PRSUs vest based on the achievement of certain predefined Company-specific performance criteria. Any unvested PRSUs will expire if it is determined the related performance criteria has not been met during the applicable three to four-year performance period. The fair value of PRSUs is estimated based on the closing sal... | text | 34.4 | monetaryItemType | text: <entity> 34.4 </entity> <entity type> monetaryItemType </entity type> <context> PRSUs vest based on the achievement of certain predefined Company-specific performance criteria. Any unvested PRSUs will expire if it is determined the related performance criteria has not been met during the applicable three to four-... | us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue |
Under the Amended 2018 ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85 % of (i) the market value per share of the common stock on the first day of the offering perio... | text | 85 | percentItemType | text: <entity> 85 </entity> <entity type> percentItemType </entity type> <context> Under the Amended 2018 ESPP, eligible employees may purchase shares of our common stock at a discount semi-annually based on a percentage of their annual compensation. The discounted purchase price is equal to the lower of 85 % of (i) th... | us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent |
As of December 31, 2023, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2023 and 2022, we recorded a valuation allowance of $ 88.9 million and $ 67.0 million, respectively, ag... | text | 88.9 | monetaryItemType | text: <entity> 88.9 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2023 and 2022, we... | us-gaap:DeferredTaxAssetsValuationAllowance |
As of December 31, 2023, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2023 and 2022, we recorded a valuation allowance of $ 88.9 million and $ 67.0 million, respectively, ag... | text | 67.0 | monetaryItemType | text: <entity> 67.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, our deferred tax assets were primarily the result of net operating loss carry forwards, capitalized research costs, acquired intangible assets and tax credit carryforwards. As of December 31, 2023 and 2022, we... | us-gaap:DeferredTaxAssetsValuationAllowance |
As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December 31, 2023, management determined there was sufficient positive evidence to conclude that it is more likely than not deferred ta... | text | 362.6 | monetaryItemType | text: <entity> 362.6 </entity> <entity type> monetaryItemType </entity type> <context> As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December 31, 2023, management determined there w... | us-gaap:DeferredTaxAssetsLiabilitiesNet |
As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December 31, 2023, management determined there was sufficient positive evidence to conclude that it is more likely than not deferred ta... | text | 88.9 | monetaryItemType | text: <entity> 88.9 </entity> <entity type> monetaryItemType </entity type> <context> As of each reporting date, management considers new evidence, both positive and negative, that could affect its assessment of the future realizability of our deferred tax assets. As of December 31, 2023, management determined there wa... | us-gaap:DeferredTaxAssetsValuationAllowance |
As of December 31, 2023, we had state and foreign income tax net operating loss carryforwards of $ 286.0 million and $ 134.3 million, respectively. We had no federal income tax operating loss carryforwards as of December 31, 2023. California net operating losses will begin to expire in 2029 unless previously utilized a... | text | 286.0 | monetaryItemType | text: <entity> 286.0 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had state and foreign income tax net operating loss carryforwards of $ 286.0 million and $ 134.3 million, respectively. We had no federal income tax operating loss carryforwards as of December 31, 2023. Ca... | us-gaap:OperatingLossCarryforwards |
As of December 31, 2023, we had state and foreign income tax net operating loss carryforwards of $ 286.0 million and $ 134.3 million, respectively. We had no federal income tax operating loss carryforwards as of December 31, 2023. California net operating losses will begin to expire in 2029 unless previously utilized a... | text | 134.3 | monetaryItemType | text: <entity> 134.3 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had state and foreign income tax net operating loss carryforwards of $ 286.0 million and $ 134.3 million, respectively. We had no federal income tax operating loss carryforwards as of December 31, 2023. Ca... | us-gaap:OperatingLossCarryforwards |
As of December 31, 2023, we had state and foreign income tax net operating loss carryforwards of $ 286.0 million and $ 134.3 million, respectively. We had no federal income tax operating loss carryforwards as of December 31, 2023. California net operating losses will begin to expire in 2029 unless previously utilized a... | text | no | monetaryItemType | text: <entity> no </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had state and foreign income tax net operating loss carryforwards of $ 286.0 million and $ 134.3 million, respectively. We had no federal income tax operating loss carryforwards as of December 31, 2023. Calif... | us-gaap:OperatingLossCarryforwards |
As of December 31, 2023, we had state R&D tax credit carryforwards of $ 85.6 million. California R&D tax credits carry forward indefinitely, while R&D tax credits related to other states will begin to expire in 2033 unless previously utilized. | text | 85.6 | monetaryItemType | text: <entity> 85.6 </entity> <entity type> monetaryItemType </entity type> <context> As of December 31, 2023, we had state R&D tax credit carryforwards of $ 85.6 million. California R&D tax credits carry forward indefinitely, while R&D tax credits related to other states will begin to expire in 2033 unless previously ... | us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch |
We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $ 3.1 million and $ 1.2 million, respectively, as of December 31, 2023 and 2022. We had accruals for penalties relates to income tax matters of $ 2.2 million and $ 0.4 m... | text | 3.1 | monetaryItemType | text: <entity> 3.1 </entity> <entity type> monetaryItemType </entity type> <context> We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $ 3.1 million and $ 1.2 million, respectively, as of December 31, 2023 and 2022. We ... | us-gaap:IncomeTaxExaminationInterestAccrued |
We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $ 3.1 million and $ 1.2 million, respectively, as of December 31, 2023 and 2022. We had accruals for penalties relates to income tax matters of $ 2.2 million and $ 0.4 m... | text | 1.2 | monetaryItemType | text: <entity> 1.2 </entity> <entity type> monetaryItemType </entity type> <context> We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $ 3.1 million and $ 1.2 million, respectively, as of December 31, 2023 and 2022. We ... | us-gaap:IncomeTaxExaminationInterestAccrued |
We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $ 3.1 million and $ 1.2 million, respectively, as of December 31, 2023 and 2022. We had accruals for penalties relates to income tax matters of $ 2.2 million and $ 0.4 m... | text | 2.2 | monetaryItemType | text: <entity> 2.2 </entity> <entity type> monetaryItemType </entity type> <context> We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $ 3.1 million and $ 1.2 million, respectively, as of December 31, 2023 and 2022. We ... | us-gaap:IncomeTaxExaminationPenaltiesAccrued |
We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $ 3.1 million and $ 1.2 million, respectively, as of December 31, 2023 and 2022. We had accruals for penalties relates to income tax matters of $ 2.2 million and $ 0.4 m... | text | 0.4 | monetaryItemType | text: <entity> 0.4 </entity> <entity type> monetaryItemType </entity type> <context> We recognize interest and penalties related to income tax matters in income tax expense. We had accruals for interest related to income tax matters of $ 3.1 million and $ 1.2 million, respectively, as of December 31, 2023 and 2022. We ... | us-gaap:IncomeTaxExaminationPenaltiesAccrued |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.